Elsaadi S et al. found that human myeloma cells with phosphoglycerate dehydrogenase (PHGDH, the first and rate-limiting enzyme in the de novo serine synthesis pathway) expression knocked down exhibited increased sensitivity to BTZ and lower intracellular redox capacity [37]. The gene discussed is PHGDH; the disease is plasma cell myeloma.